In last trading session, TCR2 Therapeutics Inc. (NASDAQ:TCRR) saw 0.59 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $4.01 trading at $0.1 or 2.56% at ring of the bell on the day assigns it a market valuation of $153.62M. That closing price of TCRR’s stock is at a discount of -775.31% from its 52-week high price of $35.10 and is indicating a premium of 3.49% from its 52-week low price of $3.87. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.71 million shares which gives us an average trading volume of 846.97K if we extend that period to 3-months.
For TCR2 Therapeutics Inc. (TCRR), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 2.10. Splitting up the data highlights that, out of 9 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.74 in the current quarter.
TCR2 Therapeutics Inc. (NASDAQ:TCRR) trade information
Upright in the green during last session for gaining 2.56%, in the last five days TCRR remained trading in the red while hitting it’s week-highest on Tuesday, 01/11/22 when the stock touched $4.01 price level, adding 5.2% to its value on the day. TCR2 Therapeutics Inc.’s shares saw a change of -13.95% in year-to-date performance and have moved -2.91% in past 5-day. TCR2 Therapeutics Inc. (NASDAQ:TCRR) showed a performance of -20.59% in past 30-days. Number of shares sold short was 2.0 million shares which calculate 2.72 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $22.56 to the stock, which implies a rise of 82.23% to its current value. Analysts have been projecting $7.00 as a low price target for the stock while placing it at a high target of $42.00. It follows that stock’s current price would drop -947.38% in reaching the projected high whereas dropping to the targeted low would mean a loss of -74.56% for stock’s current value.
TCR2 Therapeutics Inc. (TCRR) estimates and forecasts
Statistics highlight that TCR2 Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -71.30% of value to its shares in past 6 months, showing an annual growth rate of -10.42% while that of industry is 16.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -34.50% in the current quarter and calculating -27.60% decrease in the next quarter.
In 2022, company’s earnings growth rate is likely to be around 48.10% while estimates for its earnings growth in next 5 years are of 0.00%.
TCR2 Therapeutics Inc. is more likely to be releasing its next quarterly report between March 09 and March 14 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
TCR2 Therapeutics Inc. (NASDAQ:TCRR)’s Major holders
Insiders are in possession of 0.84% of company’s total shares while institution are holding 84.08 percent of that, with stock having share float percentage of 84.80%. Investors also watch the number of corporate investors in a company very closely, which is 84.08% institutions for TCR2 Therapeutics Inc. that are currently holding shares of the company. MPM Asset Management, LLC is the top institutional holder at TCRR for having 4.05 million shares of worth $34.47 million. And as of Sep 29, 2021, it was holding 10.60% of the company’s outstanding shares.
The second largest institutional holder is Redmile Group, LLC, which was holding about 3.82 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 9.99% of outstanding shares, having a total worth of $32.48 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 0.95 million shares of worth $8.12 million or 2.50% of the total outstanding shares. The later fund manager was in possession of 0.75 million shares on Sep 29, 2021, making its stake of worth around $6.39 million in the company or a holder of 1.97% of company’s stock.